cbdMD, Inc. YCBD
cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. The majority of our products are anchored by hemp-derived cannabinoids, including broad-spectrum and full-spectrum CBD formulations, hemp-derived Delta-9 THC products (where permitted by law), and a range of functional products designed to address key wellness needs such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. Our approach centers on combining scientific rigor with high manufacturing standards to produce consistent, safe, and reliable products that meet both consumer expectations and evolving regulatory requirements.
Last close
0.36
2026-10-23
Market cap
$4.1M
2026-06-30 share count
52-week range
0.33 - 2.56
Valuation FY2026 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $19.2M | $19.9M | $25.1M | $37.1M | $47.3M | $41.9M | $23.7M | $459.1K | $4.5M |
| Cost of revenue | — | $7.2M | $7.5M | $9.2M | $13.1M | $14.5M | $15.5M | $9.1M | $104.0K | $1.4M |
| Gross profit | — | $12.0M | $12.0M | $15.0M | $22.3M | $30.0M | $26.4M | $14.5M | $355.1K | $3.1M |
| Total operating expenses | — | — | — | — | — | $49.6M | $44.0M | $29.3M | $2.2M | $3.4M |
| Operating income | — | -$2.2M | -$3.3M | -$22.5M | -$78.3M | -$19.6M | -$17.6M | -$14.8M | -$1.8M | -$1.4M |
| Interest expense | — | $34.3K | $29.5K | $63.7K | $16.2K | $28.9K | $39.9K | $75.1K | $0 | $500.6K |
| Pre-tax income | — | -$2.0M | -$3.7M | -$22.9M | -$70.1M | -$24.3M | $11.3M | -$47.8M | -$1.8M | -$1.4M |
| Income tax | — | $0 | $0 | $0 | $0 | $895.0K | $1.3M | $2.4M | $0 | $25.0K |
| Net income | — | -$2.0M | -$3.7M | -$22.9M | -$70.1M | -$23.4M | $12.6M | -$51.4M | $62.8K | -$1.4M |
| EPS, basic | — | -1.09 | -14.29 | -13.32 | -55.80 | -0.47 | 0.28 | -2.82 | -0.05 | — |
| EPS, diluted | — | -1.09 | -14.29 | -13.32 | -55.80 | -0.47 | 0.28 | 0.00 | 0.00 | -0.38 |
| Shares, diluted (wtd. avg.) | — | 4.0M | 539,069 | 2.0M | 1.3M | 54.9M | 45.2M | 17.9M | 7.7M | — |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | $2.3M | $2.5M | $1.8M | $6.7M | $26.4M | $14.8M | $4.7M | $4.3M | $284.2K |
| Short-term investments | — | — | — | — | $0 | $33.4K | $26.5K | $198.5K | $1.1M | $0 |
| Receivables | — | $786.4K | $621.7K | $585.3K | $273.5K | — | — | $0 | $459.0K | $0 |
| Inventory | — | $2.9M | $2.5M | $4.2M | $4.8M | $5.6M | $4.9M | $5.2M | $123.2K | $588.2K |
| Total current assets | — | $6.6M | $6.4M | $8.1M | $16.0M | $36.5M | $23.7M | $15.7M | $11.8M | $3.7M |
| Property, plant and equipment | — | $277.4K | $454.3K | $716.6K | $823.3K | $2.6M | $3.2M | $1.7M | $53.5K | $135.5K |
| Goodwill | — | — | — | $0 | $0 | $56.7M | $54.7M | $54.7M | $0 | — |
| Other intangibles | — | $2.1M | $2.9M | $3.2M | $17.8M | $23.0M | $21.6M | $21.6M | $3.2M | $3.2M |
| Total assets | — | $10.4M | $10.6M | $16.2M | $40.8M | $124.9M | $110.8M | $94.5M | $15.0M | $7.1M |
| Accounts payable | — | $1.2M | $1.5M | $1.9M | $2.0M | $3.0M | $2.9M | $3.0M | $473.7K | $397.6K |
| Total current liabilities | — | $3.2M | $8.6M | $4.7M | $5.3M | $6.9M | $7.7M | $3.7M | $970.0K | $1.5M |
| Long-term debt | — | — | — | $9 | $125.5K | $109.0K | $264.4K | — | — | — |
| Total liabilities | — | $3.2M | $8.6M | $7.2M | $9.4M | $21.7M | $31.7M | $56.9M | $998.5K | $1.9M |
| Retained earnings | — | -$179.4M | -$182.1M | -$174.4M | -$147.4M | -$73.3M | -$47.4M | -$59.6M | -$6.7M | -$6.3M |
| Total equity | — | $7.2M | $2.0M | $9.0M | $31.4M | $103.1M | $79.2M | $37.6M | $14.0M | $5.1M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$1.5M | -$352.8K | -$4.3M | -$15.0M | -$14.1M | -$10.7M | -$15.4M | -$5.6M | -$2.3M |
| Depreciation and amortisation | — | $361.1K | $452.3K | $404.3K | $949.0K | $1.0M | $720.8K | $289.6K | $222.5K | $71.3K |
| Stock-based compensation | — | — | — | — | — | $1.3M | $1.9M | $2.5M | $639.6K | $56.5K |
| Capital expenditure | — | $184.2K | $190.0K | $297.5K | $688.7K | $342.0K | $1.3M | $1.2M | $23.6K | $8.0K |
| Investing cash flow | — | -$184.2K | -$290.0K | $702.5K | -$688.7K | -$2.6M | -$1.6M | -$2.1M | -$683.6K | $192.0K |
| Financing cash flow | — | $1.4M | $1.3M | -$1.3M | -$4.0M | $28.2M | $22.4M | $17.9M | $10.3M | $2.4M |
| Dividends paid | — | — | — | — | — | $2.6M | $366.9K | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-001542.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M | $459.1K | $23.7M | $41.9M | $47.3M | $37.1M | $25.1M | $19.9M | $19.2M | — |
| Gross profit | $3.1M | $355.1K | $14.5M | $26.4M | $30.0M | $22.3M | $15.0M | $12.0M | $12.0M | — |
| Net income | -$1.4M | $62.8K | -$51.4M | $12.6M | -$23.4M | -$70.1M | -$22.9M | -$3.7M | -$2.0M | — |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2844
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CL | COLGATE PALMOLIVE CO | $74.97B | 35.8x | 1.4% |
| EL | ESTEE LAUDER COMPANIES INC | $39.37B | 217.3x | 5.0% |
| KVUE | Kenvue Inc. | $37.59B | 25.8x | -2.1% |
| ELF | e.l.f. Beauty, Inc. | $6.74B | 259.6x | 24.6% |
| IPAR | INTERPARFUMS INC | $3.69B | 22.0x | 2.5% |
| COTY | COTY INC. | $2.84B | — | -1.5% |
| EPC | EDGEWELL PERSONAL CARE Co | $1.29B | 52.9x | -1.3% |
| WALD | Waldencast plc | $100.3M | — | -0.7% |